PDS Biotechnology will host a virtual KOL event on Oct. 15 to present phase 2 outcomes for PDS0301 in advanced liver-associated cancers, with a focus on metastatic colorectal cancer. NCI’s Jonathan M. Hernandez will join as the company sharpens its mCRC focus.
published
PDS Biotechnology will host a virtual KOL event on Oct. 15 to present phase 2 outcomes for PDS0301 in advanced liver-associated cancers, with a focus on metastatic colorectal cancer. NCI’s Jonathan M. Hernandez will join as the company sharpens its mCRC focus.
Latest documented BWB result
$NVDA market result
Exit $NVDA with $3 profit per share
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.